Virometix AG is at the forefront of developing innovative synthetic vaccines aimed at combating infectious diseases and cancer. The company utilizes a proprietary technology platform based on Synthetic Virus-Like Particles (SVLPs), which allows for the optimal presentation of antigens in a multivalent form. This platform is designed to enhance immune responses by incorporating T-helper epitopes and Toll-like receptor (TLR) ligands, creating a self-adjuvanted system that effectively stimulates both B and T-cell responses. Virometix's approach includes the use of Synthetic Antigen Mimetics (SAMs), which are engineered to mimic native epitopes, thereby improving the precision and efficacy of the immune response.

Virometix's pipeline features a range of vaccine candidates, including a serotype-independent vaccine for Streptococcus pneumoniae and a first-in-class vaccine for Respiratory Syncytial Virus (RSV). The company is also developing vaccines targeting various coronaviruses and exploring options for cancer immunotherapy. By leveraging its modular and flexible SVLP technology, Virometix aims to create effective and scalable vaccine solutions that address significant unmet medical needs, while also fostering collaborations to enhance its research and development efforts.

Switzerland

Virometix is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases

Virometix

Company Details